HOOK News and Press, HOOKIPA Pharma Inc. From 04/20/22

NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Tim Reilly, Ph.D. to its Boar...

Hookipa Pharma's (NASDAQ:HOOK) stock rose April 13 after it said that preclinical data showed its arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens. The company said that preclinical data presented at AACR (abstract #4198) sho...

Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on arenaviral immunotherapy targeting tumor self-antigens, reinforcing scientific appro...

NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor me...

Gainers: Lulu's Fashion Lounge Holdings (LVLU) +12%. Chicken Soup for the Soul Entertainment (CSSE) +8%. American Outdoor Brands (AOUT) +7%. Immuneering Corporation (IMRX) +6%. Service Properties Trust (SVC) +5%. Losers: Spero Therapeutics (SPRO) -24%. Duck Creek Tech...

Several data readouts of HB-200 alone and in combination with KEYTRUDA for treatment of HPV16+ HNSCC patients are expected in 2022. An amended agreement with Gilead Sciences, for arenavirus platform to develop treatments for HIV and HBV, established $54 million in commitment cash. ...

HOOKIPA Pharma Inc. (HOOK) Q4 2021 Earnings Conference Call March 24, 2022 08:30 AM ET Company Participants Matthew Beck - Executive Director, Investor Relations Joern Aldag - Chief Executive Officer Reinhard Kandera - Chief Financial Officer Igor Matushansky - Chief Medical Officer & Glo...

Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...

The following slide deck was published by HOOKIPA Pharma Inc. in conjunction with their 2021 Q4 earnings call. For further details see: HOOKIPA Pharma Inc. 2021 Q4 - Results - Earnings Call Presentation

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...